← Back to front page
Asia · Regional markets · CNBC-TV18

Biocon shares gain after US FDA approves cancer drug biosimilar

Published by CNBC-TV18 · India 1 h ago
Biocon shares gain after US FDA approves cancer drug biosimilar - CNBC TV18
Biocon shares gain after US FDA approves cancer drug biosimilar - CNBC TV18 · CNBC-TV18

Detailed summary

The biosimilar to Perjeta has been approved for patients with metastatic and early-stage HER2-positive breast cancer. Biocon expects to launch the drug in the US in Q3 2028 under…

Shares of Biocon gained on Monday, November 16, after the company secured US Food and Drug Administration (FDA) approval for Pebrilzo, a biosimilar to the cancer drug Perjeta.

The approval was its fifth USFDA-approved oncology biosimilar, the company said in a regulatory filing on Monday.

"The US FDA approval of PEBRILZO, our biosimilar pertuzumab, marks another significant milestone in Biocon's journey to expand access to high-quality biosimilars," said Shreehas Tambe, the company's CEO and Managing Director.

The company said the approval would help it expand affordable treatment options for patients with HER2-positive breast cancer.

Pebrilzo is a monoclonal antibody that blocks HER2 receptors on cancer cells. It is used to treat HER2-positive breast cancer, an aggressive form of the disease.

The drug is designed to have no clinically meaningful differences from Perjeta in terms of safety, quality and effectiveness, according to the filing.

The USFDA approved Pebrilzo for patients with metastatic and early-stage HER2-positive breast cancer. Its label also carries warnings about possible heart problems and harm to unborn babies and requires regular cardiac checks and contraception during treatment, the filing said.

In September, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended marketing approval for Pebrilzo in Europe. The recommendation covers HER2-positive breast cancer across multiple disease stages. Under a licensing agreement with Genentech, Pebrilzo is expected to enter the US market in the third quarter of 2028.

Biocon shares were trading 0.15% down at ₹363.50 as of 10:47 am on Monday after closing, 1.86% lower on Friday, November 13.

Opening of the article, excerpted from CNBC-TV18. To read the rest, open the article on the publisher's site.

Read the full article on CNBC-TV18 Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.cnbctv18.com)

Also worth reading